로딩 중...
52주 최고가 대비 98.6% 위치
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $516.4M | $618.7M | $610.8M | $642.8M |
| 영업이익 | - | $-167.9M | $-204.3M | $-194.6M | $-110.9M |
| 당기순이익 | - | $-166.0M | $-255.1M | $-182.6M | $-43.5M |
| 잉여현금흐름 (FCF) | - | $-165.3M | $-64.7M | $-6.7M | $130.1M |
| 수익성 비율 | |||||
| 영업이익률 | - | -32.5% | -33.0% | -31.9% | -17.2% |
| 순이익률 | - | -32.1% | -41.2% | -29.9% | -6.8% |
| ROE (자기자본이익률) | - | -20.6% | -34.4% | -25.7% | -5.5% |
| ROA (자산이익률) | - | -16.1% | -26.4% | -19.9% | -4.2% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 19.8% | -1.3% | 5.2% |
| EPS 성장률 (YoY) | - | - | -49.3% | 30.3% | 77.0% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | 6.8x | 6.6x | 2.5x | 3.0x |
| PSR (주가매출배수) | - | 10.6x | 7.9x | 2.9x | 3.7x |
| FCF Yield | - | -3.0% | -1.3% | -0.4% | 5.5% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.12 | 0.13 | 0.12 | 0.11 |
| 유동비율 | - | 4.85 | 4.69 | 4.97 | 4.46 |
MOLINA HEALTHCARE INC
$179.86
$9.4B